Division of Cardiology, Cardiovascular Medical Center, and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan; National Yang Ming Chiao Tung University, School of Medicine, Faculty of Medicine, Taipei, Taiwan
Division of Cardiology, Department of Internal Medicine, National Cheng Kung University Hospital, College of Medicine, National Cheng Kung University; Institute of Clinical Medicine, College of Medicine, National Cheng Kung University
Interests: Stem cell research; Cardiac regeneration; Echocardiography; Cancer therapy related cardiac dysfunction; Cardio-oncology
Pei-Wei Shueng, MD
Division of Radiation Oncology, Department of Radiology, Far Eastern Memorial Hospital, New Taipei City, Taiwan; National Yang Ming Chiao Tung University, School of Medicine, Faculty of Medicine, Taipei, Taiwan
Interests: Stereotactic Body Radiation Therapy (SBRT); Image-Guided Radiotherapy (IGRT); Radiation related cardiotoxicity; Radiation related pneumonitis
Special Issue Information
The two top causes of death in the world are cancer and cardiovascular disease, and cardiovascular demands to the care of cancer patients are common and important given the implications for morbidity and mortality. Cancer treatment has advanced rapidly from surgery, cytotoxic chemotherapy, radiation therapy, and targeted and immune-based therapies over the past decades. These advances have led to an increase in the number of cancer survivors, however an emerging issue associated with these new cancer therapies is side effects on the cardiovascular system, which cause different spectrums of morbidity and mortality. In order to explor and detect cancer therapeutics–related cardiovascular dysfunction and mitigate its progression, the both fields are closely intertwined with each other.
This Special Issue takes specific focus on the current state of cardio-oncology field and especially cancer therapy-related cardiac dysfunction—exploring the mechnisms, reviewing the current status including dignoastic and imaging modalites, team-based care and personalised approaches, and clinical unmet needs, with recommendations to minimise the risk of cardiovascular toxicity from cancer therapies and the development of dedicated cardio-oncology care.
Dr. Yen-Wen Wu, Dr. Hung-Ju Lin, Dr. Yen-Wen Liu and Dr. Pei-Wei Shueng
Manuscript Submission Information
Manuscripts should be submitted online at https://rcm.imrpress.org by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a double-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on theInstructions for Authorspage. Reviews in Cardiovascular Medicine is an international peer-reviewed open access quarterly journal published by IMR Press.